skip to Main Content

Immunogenicity and Safety of a Third COVID-19 BNT162b2 mRNA Vaccine Dose in 5-11-Year-Olds

In this ongoing study, substantially increased ancestral SARS-CoV-2 neutralizing responses were observed 1 month after a third 10-µg BNT162b2 dose given to 5 to 11-year olds versus neutralizing responses post-dose 2. After dose 3, increased neutralizing responses against Omicron BA.1 and BA.4/BA.5 strains were also observed. The safety/tolerability profile was acceptable. (NCT04816643).

Authors: Simões, Eric A F; Klein, Nicola P; C4591007 Clinical Trial Group,; et al.

J Pediatric Infect Dis Soc. 2023 Apr 28;12(4):234-238.

PubMed abstract

Explore all studies and publications

Back To Top